ESMO Breast Cancer Virtual Meeting 2020
Benefit Shown for AKT Inhibitor in LOTUS Survival Analysis
In the phase II LOTUS trial, the addition of the AKT inhibitor ipatasertib to paclitaxel in the first-line treatment of patients with advanced triple-negative breast cancer yielded a strong numerical ...
Newer Late-Line Treatments May Change Front-Line Standard of Care in HER2-Positive Metastatic Breast Cancer
First- and second-line treatments of HER2-positive metastatic breast cancer have become the standard of care based on solid gains in overall survival, but the prevalence of resistance to these agents ...
Early Data Suggest Activity for Oral Selective Estrogen Receptor Degrader in Combination Regimen
The availability of an oral selective estrogen receptor degrader (SERD) would be good news for patients and clinicians as an alternative to intramuscular fulvestrant. The novel agent LSZ102 might fit ...
ESMO Breast 2020: Novel Biomarkers May Predict Immunotherapy Benefit in Metastatic Breast Cancer
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment...
ESMO Breast 2020: Study Finds Physical Activity, Supportive Care to Relieve Cancer-Related Fatigue May Be Underutilized by Breast Cancer Survivors
Cancer-related fatigue is a prevalent and potentially persistent issue among breast cancer survivors. A study presented by Di Meglio et al at the ESMO Breast Cancer Virtual Meeting 2020 (Abstract 183O...
ESMO Breast 2020: Ipatasertib/Paclitaxel vs Paclitaxel Alone in Advanced Triple-Negative Breast Cancer
Final analysis of the LOTUS trial has shown numerically longer overall survival with ipatasertib plus paclitaxel vs placebo plus paclitaxel in patients with inoperable locally advanced/metastatic trip...
ESMO Breast 2020: Patient Preference for Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for HER2-Positive Early Breast Cancer
At the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Meeting 2020, Joyce O’Shaughnessy, MD, of Baylor University Medical Center, reported results from an interim analysis of the ...
